The biological players involved in angiogenesis are only partially defined. Here, we report that endothelial cells (ECs) express a novel isoform of the cell-surface adhesion molecule L1CAM, termed L1-?TM. The splicing factor NOVA2, which binds directly to L1CAM pre-mRNA, is necessary and sufficient for the skipping of L1CAM transmembrane domain in ECs, leading to the release of soluble L1-?TM. The latter exerts high angiogenic function through both autocrine and paracrine activities. Mechanistically, L1-?TM-induced angiogenesis requires fibroblast growth factor receptor-1 signaling, implying a crosstalk between the two molecules. NOVA2 and L1-?TM are overexpressed in the vasculature of ovarian cancer, where L1-?TM levels correlate with tumor vascularization, supporting the involvement of NOVA2-mediated L1-?TM production in tumor angiogenesis. Finally, high NOVA2 expression is associated with poor outcome in ovarian cancer patients. Our results point to L1-?TM as a novel, EC-derived angiogenic factor which may represent a target for innovative antiangiogenic therapies.

A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing

Ghigna C
2019

Abstract

The biological players involved in angiogenesis are only partially defined. Here, we report that endothelial cells (ECs) express a novel isoform of the cell-surface adhesion molecule L1CAM, termed L1-?TM. The splicing factor NOVA2, which binds directly to L1CAM pre-mRNA, is necessary and sufficient for the skipping of L1CAM transmembrane domain in ECs, leading to the release of soluble L1-?TM. The latter exerts high angiogenic function through both autocrine and paracrine activities. Mechanistically, L1-?TM-induced angiogenesis requires fibroblast growth factor receptor-1 signaling, implying a crosstalk between the two molecules. NOVA2 and L1-?TM are overexpressed in the vasculature of ovarian cancer, where L1-?TM levels correlate with tumor vascularization, supporting the involvement of NOVA2-mediated L1-?TM production in tumor angiogenesis. Finally, high NOVA2 expression is associated with poor outcome in ovarian cancer patients. Our results point to L1-?TM as a novel, EC-derived angiogenic factor which may represent a target for innovative antiangiogenic therapies.
2019
Istituto di Genetica Molecolare "Luigi Luca Cavalli Sforza"
[object Object
[object Object
[object Object
[object Object
[object Object
[obje
[object Object
[object Object
[object Object
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/389061
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 46
  • ???jsp.display-item.citation.isi??? ND
social impact